MedTrace Logo

Bronchiectasis Phenotype Identification Model

NCT07599969 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 750

Last updated 2026-05-20

No results posted yet for this study

Summary

The Bronchiectasis Phenotype Identification Model (BPIM) is a prospective observational development-validation study within the Assiut University bronchiectasis translational research platform.

The study evaluates whether latent class trajectory analysis (LCTA)-derived bronchiectasis phenotype classes can be translated into a supervised baseline classifier for adults with non-cystic fibrosis bronchiectasis (NCFB).

Latent class trajectory analysis (LCTA) will first identify trajectory-derived phenotype classes using prospectively collected longitudinal disease-signature data. The Bronchiectasis Phenotype Identification Model (BPIM) will then be trained to predict the accepted latent class trajectory analysis (LCTA)-derived phenotype class using the locked baseline disease-signature architecture.

This study is observational and non-interventional. No treatment, medication, intervention, exposure, or management strategy is assigned by the protocol. All participants receive routine clinical care according to institutional practice and treating physician judgment.

The locked methodological disclosure, protocol, and deterministic statistical analysis plan are archived in the version-specific Zenodo record: https://doi.org/10.5281/zenodo.20157926.

Conditions

  • Bronchiectasis
  • Non-cystic Fibrosis Bronchiectasis
  • Bronchiectasis With Acute Exacerbation

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Ahmad M Shaddad, MD · Assiut University

  • Aliae A. Hussien, MD · Assiut University

  • Maiada K. Hashem, MD · Assiut University

  • Alaa S. Ali, MD · Assiut University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-11
Primary Completion
2026-11-01
Completion
2026-12-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07599969 on ClinicalTrials.gov